Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC23442	E-5842	E-5842 is a preferential sigma-1 receptor ligand, demonstrates potential atypical antipsychotic effects in vivo.
DC23416	E-5842 hydrochloride	E-5842 is a preferential sigma-1 receptor ligand, demonstrates potential atypical antipsychotic effects in vivo.
DC9387	E-64 Featured	E-64 is a natural, potent, and irreversible inhibitor of cysteine proteases; IC50 values for inhibiting cathepsins K, S, and L, in vitro, are 1.4, 4.1, and 2.5 nM, respectively.
DC23728	E64FC26	E64FC26 is a highly potent pan-style inhibitor of Protein Disulfide Isomerase (PDI) with IC50 of 1.9 uM (PDIA1), also inhibits all other members of the PDI family, including PDIA3, PDIA4, TXNDC5, and PDIA6.
DC23360	E67-2	E67-2 is a potent and selective inhibitor of H3K9 Jumonji demethylase KIAA1718 (KDM7A) with IC50 of 3.4 uM.
DC10563	E-7046 Featured	E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities.
DC21898	E7090 succinate	E7090 (E 7090) is a potent, selective, orally available inhibitor of FGFR1, -2, and -3 with IC50 of 0.71, 0.50 and 1.2 nM, weakly inhibits FGFR4 (IC50=120 nM).
DC22085	Tasurgratinib（E7090) Featured	E7090 (E 7090) is a highly potent and selective orally bioavailable inhibitor targeting FGFR1, FGFR2, and FGFR3, with IC50 values of 0.71 nM, 0.50 nM, and 1.2 nM, respectively. It exhibits significantly weaker inhibition of FGFR4, with an IC50 of 120 nM. This distinct selectivity profile positions E7090 as a promising therapeutic candidate for diseases driven by aberrant FGFR1-3 signaling, offering a targeted approach to inhibit these receptors while minimizing off-target effects on FGFR4. Its oral availability further enhances its potential as a convenient and effective treatment option for patients with FGFR-dependent conditions.
DC11062	E7107	E7107 (E-7107) is a derivative of pladienolide that targets the SF3b subunit of the spliceosome, shows significant antitumor activity in vitro and in vivo.
DC10976	E-7386 Featured	E-7386 (E7386) is a potent, orally active modulator of CBP/beta-catenin, disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 with IC50 of 55 and 73 nM, respectively.
DC11037	EB-3D	EB-3D is a novel potent and selective choline kinase ChoKα inhibitor with IC50 of 1.0 uM (purified ChoKα1), strongly impairs cell proliferation in a variety of different cancer cell lines.
DC20989	EBI-1051	EBI-1051 is a novel and orally efficacious MEK inhibitor with IC50 of 10.8 nM against MEK1, inhibits viability of colo-205 cells with IC50 of 4.7 nM.
DC23818	EBI-907	EBI-907 is a highly potent, selective, orally active B-Raf V600E inhibitor with enzyme IC50 of 7 nM, A375 cell growth IC50 of 13 nM.
DC20123	EC0489	EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor. Small molecule-drug conjugate (SMDC).
DC10980	EC-359	EC-359 (EC359) is a first-in-class, orally available inhibitor of leukemia inhibitory factor (LIF), blocks LIF-LIFR interaction and binds to LIFR with affinity of 81 nM in SPR assay.
DC20990	EC-70124	EC-70124 is a multikinase inhibitor with potent activity against several AML related kinases including FLT3, JAK, SYK or Pim kinases (Kd<10 nM).
DC21514	Ecopladib	Ecopladib (PLA 725) is a potent, selective and orally active inhibitor of cPLA2α with IC50 of 0.15 and 0.11 uM in GLU micelle and rat whole blood assays, respectively.
DC10400	Ecteinascidin 770	Ecteinascidin 770 (ET-770) is a 1,2,3,4-tetrahydroisoquinoline alkaloid with potent anti-cancer activities; inhibits U373MG cells with an IC50 of 4.83 nM.
DC10939	Edasalonexent	Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).
DC21002	Edelfosine Featured	Edelfosine is a synthetic lysophospholipid analog that selectively inhibits PLC with IC50 of 9.6 uM in fibroblasts and adenocarcinoma cells.
DC23562	Edivoxetine	Edivoxetine (LY2216684) is a novel potent, selective norepinephrine reuptake inhibitor (NERI) being evaluated as adjunctive treatment for major depressive disorder (MDD)..
DC23628	Edivoxetine hydrochloride	Edivoxetine (LY2216684) is a novel potent, selective norepinephrine reuptake inhibitor (NERI) being evaluated as adjunctive treatment for major depressive disorder (MDD)..
DC21515	Efipladib	Efipladib (PLA 902) is a potent, selective and orally active inhibitor of cPLA2α with IC50 of 20 nM for LTB4 inhibition.
DC10261	Eflornithine hydrochloride hydrate	Eflornithine(Difluoromethylornithine) inhibits polyamine biosynthesis by the selective, irreversible inhibition of ornithine decarboxylase (ODC). A chemoprotective agent that blocks angiogenesis. Its biological half-life is 8 hours.
DC20992	eFT226	eFT226 is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex.
DC9755	eFT508(Tomivosertib) Featured	Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
DC22086	EG00229 free base	EG00229 is a specific inhibitor of neuropilin-1 (NRP1)/VEGF-A interaction, inhibits the binding of biotinylated VEGFA to NRP1 with IC50 of 8 uM.
DC22087	EG01377	EG01377 is a potent and bioavailable inhibitor of the NRP1/VEGF-A interaction (Kd=1.32 uM), selective for NRP1 over the closely related protein NRP2.
DC12303	Eg5 Inhibitor V, trans-24	Eg5 Inhibitor V, trans-24 is a potent and specific Eg5 inhibitor with an IC50 of 0.65 μM, and can be used in the research of cancer.
DC23179	EGF816 mesylate	EGF816 (Nazartinib) is a potent, irreversible, mutant-selective EGFR inhibitor with Ki and Kinact of 31 nM and 0.222 min-1, respectively.

Novel inhibitors

Customized Consultation X

Your information is safe with us. * Required Fields.